26 Feb 2025 Date | | - Cons. EPS | - EPS |
27 Nov 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2024 Date | | - Cons. EPS | - EPS |
31 Jul 2024 Date | | - Cons. EPS | - EPS |
30 Jul 2024 Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
27 Nov 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2024 Date | | - Cons. EPS | - EPS |
31 Jul 2024 Date | | - Cons. EPS | - EPS |
30 Jul 2024 Date | | - Cons. EPS | - EPS |
Mortgage Finance Industry | Financial Services Sector | Mr. Kai Sun CEO | OTC PINK Exchange | AU000000MEB8 ISIN |
United Kingdom Country | 1,411 Employees | - Last Dividend | 24 Oct 2023 Last Split | - IPO Date |
TrivarX Limited, initially known as Medibio Limited, is a pioneering health technology company focused on the advancement of mental health care through innovative detection and screening technologies. Founded in 1987 and headquartered in Mount Lawley, Australia, the company has expanded its operations to both Australia and the United States. With a strong commitment to improving mental well-being, TrivarX Limited serves a dual market comprising both businesses seeking corporate health solutions and healthcare providers looking for effective tools in mental health diagnosis and management. In October 2023, the company underwent a significant rebranding to TrivarX Limited, marking a new chapter in its mission to enhance mental health care globally.
TrivarX Limited offers a range of innovative solutions designed to support mental well-being in various settings: